S
Shanghai Yiru Biotechnology
Sustainable biomaterials developed via synthetic biology methods
About Shanghai Yiru Biotechnology
Shanghai Yiru Biotechnology Co., Ltd., operating as SynMetabio, was founded in 2021 and is headquartered in Shanghai, China. The company develops next-generation sustainable biomaterials by integrating biotechnology with materials modification science. SynMetabio leverages synthetic biology, including gene editing and precision fermentation, to create novel bio-based materials from recycled biomass waste like discarded fruit and straw. These materials are designed to offer unique visual textures, scents, and tactile qualities.
Read full description
The company's product line includes bio-based leather, mycelium-based materials, and other biomaterials. These products serve a wide range of industries, including fashion, furniture, and automotive. For example, the firm has developed a bio-based leather called Naro and has partnered with Anta to create sneakers from mycelium material. In a collaboration with Dole, SynMetabio is converting waste fruit into 100% bio-based materials using mycelium.
The company was founded by Su Rui, who, as an undergraduate at ShanghaiTech University, developed an interest in the intersection of biology and materials science. SynMetabio has received funding from investors such as Miracleplus, Linear Capital, Danen Capital, and K2VC. With a research and development center of nearly 2,000 square meters, the company has established a platform for the development and pilot production of microbial fiber materials.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- China
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health, Chemicals
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biomaterials, Synthetic Biology, Sustainable Development Goals, Advanced Materials, Climate Tech, Circular Economy, precision fermentation
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Shanghai Yiru Biotechnology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2026 | $14M | $55M | Chaosheng Capital · Hedera Finances · Ordos Group | ↗ |
| SEED✓Equity / VC | Apr 2024 | $2.8M | $14M | MiraclePlus · Star Capital · Linear · Danen Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Yiru Biotechnology is 80 monthly website visits, down 87.9% over the last three months. Shanghai Yiru Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Linear Capital
MiraclePlus- K2K2VC
Danen Capital
Star Capital
Linear
Series A3 investors entered at this stage
- HFHedera Finances
- OGOrdos Group
- CCChaosheng Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Yiru Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Yiru Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.